The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read More
LEO Pharma Acquires Gene Therapy Pioneer Replay to Revolutionize Treatment for Rare Genetic Dermatological Diseases
In a landmark move poised to redefine the landscape of dermatological therapeutics, LEO Pharma, a global leader in medical dermatology,…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
An ambitious new international collaboration, bolstered by a prestigious pan-European EUREKA grant, is set to revolutionize the treatment landscape for…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
Microplastics Linked to Neurodegenerative Diseases Through Multiple Biological Pathways According to New International Study
Recent scientific investigations have unveiled a concerning correlation between the pervasive presence of microplastics in the environment and the rising…
Read More
Evogene, Systasy and LMU University Hospital Munich team up on AI-driven drug discovery for inflammatory diseases
A groundbreaking international collaboration, fortified by a prestigious pan-European EUREKA grant, has been officially launched to pioneer the development of…
Read More
Sanofi Secures Global Rights to Kali Therapeutics’ Promising Tri-Specific Antibody KT501 for Autoimmune Diseases in a Landmark $1.23 Billion Deal
Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
